Dysregulated expressions of KRAS, p53, and CTLA-4 (cytotoxic T-lymphocyte-associated protein) contribute to tumor-immune system crosstalk and can influence the expression of immune checkpoint molecules. Here, KRAS is linked to neoplasm.